PBAC November Meeting - Community input to Hepatitis Australia Submission

Thank you to those who added their voice to inform our submission to PBAC.  The medicines being considered at the November meeting of PBAC include:

  • Sofosbuvir (400mg) + velpatasvir (100mg) – Epclusa® by Gilead Sciences
  • Ledipasvir (90mg) + sofosbuvir (400mg) – Harvoni® by Gilead Sciences
  • Paritaprevir (75mg) + ritonavir (50mg) + ombitasvir (12.5mg) – Technivie® by AbbVie

The most significant thing to note regarding these applications is that it heralds the first pan-genotypic, interferon-free regimens for hepatitis C. Epclusa is a new treatment for genotypes 1-6 and Gilead is also seeking to expand the use of Harvoni to other genotypes. Technivie is for the treatment of genotype 4.

We partnered with The Center for Community-Driven Research (CC-DR) to gather information from people living with hepatitis C who will benefit from the latest medicines to be considered by the Pharmaceutical Benefits Advisory Committee. In particular we sought input from people living with hepatitis C genotypes 2, 3, 4, 5 and 6.

Our submission has been submitted and as soon as we here of an outcome from the PBAC meeting we will provide further updates.

Page Updated: 10 October 2016